Differences in Factors Linked to Heart Failure Between Men and Women
Discover how heart failure risk factors differ between men and women, emphasizing the importance of personalized medical approaches for better outcomes.
Recent research has shed light on the varying factors associated with heart failure in men and women, emphasizing the importance of sex-specific risk profiles. According to a study published on August 22, 2025, in the Journal of Primary Care and Community Health, women with heart failure with preserved ejection fraction (HFpEF) tend to be older and have higher rates of conditions such as asthma, osteoarthritis, depression, hypothyroidism, and anxiety compared to men with similar heart failure types. The study analyzed 460 women and 258 men with HFpEF and found that the likelihood of developing HFpEF increased with age, higher body mass index (BMI), and the presence of rheumatological or mental health disorders among women.
In the case of heart failure with reduced ejection fraction (HFrEF), the study included 225 women and 250 men. It revealed that women with HFrEF had higher prevalence rates of asthma, depression, hypothyroidism, and anxiety. Notably, Black women showed a greater odds ratio for HFrEF, indicating a significant racial disparity. The researchers noted that women with heart failure often present with different comorbidities compared to men, suggesting a need for tailored treatment approaches.
Overall, this study highlights that certain health conditions and demographic factors influence heart failure risk differently in men and women. Recognizing these sex-specific differences is crucial for improving prevention, diagnosis, and management strategies for heart failure.
Source: https://medicalxpress.com/news/2025-08-variables-heart-failure-men-women.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Research Shows Flavor Bans Reduce Youth Vaping but May Impact Cigarette Trends
Flavor bans on e-cigarettes significantly reduce youth and adult vaping, but may slow the decline in cigarette smoking among youth. Research highlights the need for balanced tobacco control strategies.
Lecanemab: A Well-Tolerated Treatment for Early-Stage Alzheimer's Disease in Real-World Settings
Recent studies indicate that lecanemab, an Alzheimer's drug, is safe and well tolerated outside clinical trials, especially when administered in specialized outpatient clinics. The treatment can slow disease progression with minimal risk of severe side effects, particularly in patients with early-stage Alzheimer's.
Massachusetts Hospital Under Scrutiny Over Brain Tumor Cluster Among Nurses
Concerns rise as a cluster of benign brain tumors among nurses at Newton-Wellesley Hospital prompts ongoing investigations and questions about workplace safety. Experts and unions are calling for more comprehensive testing to ensure hospital environmental safety.
World Health Organization Confirms No Link Between Tylenol, Vaccines, and Autism
The World Health Organization has confirmed that there is no scientific evidence linking Tylenol or vaccines to autism, countering recent unproven claims. Learn more about the facts and safety recommendations.